HER2-negative advanced breast cancer – regardless of their PIK3CA/AKT1/PTEN mutational status – and is now in phase 3 testing; 3) Daprodustat: GSK is vying to become the first drug in the HIF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback